Datapoint: Jakafi Approved for Chronic GVHD

The FDA last week approved Incyte Corp.’s JAK inhibitor Jakafi for the treatment of chronic graft-versus-host disease (GVHD) in patients that have not responded to one or two other lines of systemic therapy. Jakafi, which is already approved for the acute form of the disease, currently holds covered or better status for 70% of all insured lives.

SOURCE: MMIT Analytics, as of 9/23/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 14

Datapoint: Ochsner to Launch MA Org in Louisiana

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 13

Datapoint: Three States to Launch New Exchange Marketplaces

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 12

Datapoint: Centene Takes on Major Medicare Expansion for 2022

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today